Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Paul R. Walker, Andrea De Giglio et al.|Cancer Immunology Immunotherapy|2020Cited by 97
Safety of High-Dose Melphalan (200 Mg/M2) as Conditioning for Autologous Stem Cell Transplantation for Myeloma in Elderly PatientsAmrita Desai, Krishna V. Komanduri, Amer Beitinjaneh et al.|Transplantation and Cellular Therapy|2017Cited by 4
A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancerPatrick M. Boland, Heinz‐Josef Lenz, Kristen K. Ciombor et al.|Investigational New Drugs|2024Cited by 4
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortAbdul Rafeh Naqash, Paul R. Walker, Biagio Ricciuti et al.|Cancer Immunology Immunotherapy|2020Cited by 3